Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cellfluxx
- Development stage
- Unknown
- Lead developer
- Ruhrpharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cellfluxx is a nutraceutical supplement developed by Ruhrpharm, formulated with pomegranate extract and a complex of amino acids to provide antioxidant support and cellular protection. The pomegranate component is rich in polyphenols, such as ellagitannins, which serve as potent scavengers of reactive oxygen species (ROS), thereby mitigating oxidative stress and potential DNA damage. The inclusion of amino acids supports various metabolic pathways and cellular repair mechanisms. It is primarily marketed in Germany for general health maintenance and the protection of cells from oxidative damage.
- Brand names
- Cellfluxx
Beyond the preview
Go deeper on Cellfluxx.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cellfluxx.